Investigational drug · Phase 3
Orelabrutinib
Also called: ICP-022
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
9 still active
All registered trials
115
Any phase or sponsor naming "Orelabrutinib"
First trial start
2019
Nov 18, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Orelabrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mantle Cell Lymphoma
- Part 1:r/r B-cell Malignancies
- Part 2:B-cell Malignancies
- Relapsed/Refractory Marginal Zone Lymphoma
- Multiple Sclerosis (MS) Primary Progressive
- Relapsed/Refractory Marginal Zone Lymphoma (MZL)
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Secondary Progressive Multiple Sclerosis
- Hematologic Malignancies
- Treatment-naїve Mantle Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Multiple sclerosis · Hematology and blood cancers · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Orelabrutinib" as an intervention, largest first.
- Genotype-guided Treatment in DLBCLPivotal-lookingStatus unknown
Ruijin HospitalAcademic, hospital or other
NCT05351346 · 1,100 participants (planned) · Start Jun 1, 2022 · Primary completion Jun 1, 2026
Drug: Rituximab; Cyclophosphamide and 6 more · For: Diffuse Large B Cell Lymphoma
Sites: Shanghai, China
- Current Status of BTKi Treatment for CLL/SLL in ChinaStatus unknown
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06508684 · 1,000 participants (planned) · Start Jul 13, 2024 · Primary completion Feb 12, 2025
Drug: BTK inhibitor · For: CLL/SLL
Sites: Nanjin, China
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPivotal-lookingRecruiting
Zenas BioPharma (USA), LLCIndustry
NCT07299019 · 990 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 2030
Drug: Orelabrutinib; Placebo · For: Secondary Progressive Multiple Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fullerton, California · 98 sites in all
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPivotal-lookingRecruiting
Zenas BioPharma (USA), LLCIndustry
NCT07067463 · 705 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 2030
Drug: Orelabrutinib; Placebo · For: Multiple Sclerosis (MS) Primary Progressive
Sites: Pheonix, Arizona; Scottsdale, Arizona; West Hollywood, California · 86 sites in all
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaPivotal-lookingNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT07719855 · 652 participants (planned) · Start Jul 2026 · Primary completion Jul 2030
Drug: Orelabrutinib; obinutuzumab and 6 more · For: Follicular Lymphoma ( FL)
Sites: Shanghai, China
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLPivotal-lookingNot yet recruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06516978 · 528 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2028
Drug: Polatuzumab vedotin; Rituximab and 9 more · For: Diffuse Large B Cell Lymphoma
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLPivotal-lookingRecruiting
InnoCare Pharma Inc.Industry
NCT06363994 · 476 participants (planned) · Start May 29, 2024 · Primary completion Jun 25, 2031
Drug: Orelabrutinib; Bendamustine Injection and 2 more · For: Mantle Cell Lymphoma
Sites: Beijing, China; Bengbu, China; Changchun, China · 39 sites in all
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaPivotal-lookingRecruiting
Guangzhou Lupeng Pharmaceutical Company LTD.Industry
NCT07377578 · 394 participants (planned) · Start Feb 5, 2026 · Primary completion May 30, 2031
Drug: Rocbrutinib; Ibrutinib and 3 more · For: Mantle Cell Lymphoma
Sites: Beijing, China; Nanning, China
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06082102 · 324 participants (planned) · Start Dec 19, 2023 · Primary completion Aug 31, 2028
Drug: Orelabrutinib; Rituximab and 2 more · For: Relapsed/Refractory Marginal Zone Lymphoma
Sites: Bengbu, China; Beijing, China; Guangzhou, China · 19 sites in all
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaPivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07896590 · 292 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: Orelabrutinib; ICP-248 · For: Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Sites: Bozhou, China; Hefei, China; Beijing, China · 46 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Orelabrutinib plus R-CHOP in patients with newly diagnosed non-GCB double-expressor DLBCL: A single-arm, phase II study.
Yang Y, Zhao Y, Wu W, et al. · Br J Haematol 2026
- Bruton's tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence.
González-López TJ, Kapur R · Blood Vessel Thromb Hemost 2026
- Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials.
Joerg L, Stolyar J, McGovern J, et al. · J Drugs Dermatol 2026
- Salicylic Acid as a Food-Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation-Predominant IBS.
Duan M, Huang L, Xu Y, et al. · Food Sci Nutr 2026
- Case Report: Relapsed acquired hemophilia A following prednisone-rituximab therapy successfully treated with orelabrutinib.
Guo Y, Zhang F, Zuo Y, et al. · Front Immunol 2026
- Efficacy and safety of orelabrutinib plus R-CDOP as first-line therapy in diffuse large B-cell lymphoma with high-risk CNS-IPI: a prospective, multicenter, single-arm, phase II study.
Guo Y, Wang J, Lei H, et al. · Front Oncol 2026
Also in development for Mantle Cell Lymphoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials
Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.